Briquilimab for Allergic Asthma

Phase 1

Waitlist Available

Research Sponsored by Jasper Therapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Positive methacholine challenge at baseline (concentration of methacholine causing 20% decrease in FEV1 [PC20] PC20 ≤ 16 mg/mL or PD20 equivalent to ≤400µg)

Men and women 18 to 65 years of age with stable allergic asthma

Must not have

Lung disease other than allergic asthma

Women actively seeking pregnancy or who are not using adequate contraception

Timeline

Screening 3 weeks

Treatment Varies

Follow Up from signing the informed consent form (icf) through end of trial (eot) visit (up to 4.5 months)

Summary

This trial is testing a new drug called briquilimab for allergic asthma using a single dose to see how effective it is compared to a placebo. The study aims to understand the impact of the drug

Who is the study for?

This trial is for individuals with allergic asthma. Participants should be healthy enough to undergo an allergen challenge and have a confirmed diagnosis of allergic asthma. Specific details about age, previous treatments, or other health conditions that might affect eligibility are not provided.

What is being tested?

The study tests the safety and effectiveness of Briquilimab compared to a placebo in treating allergic asthma. It's a single-dose study where participants receive either Briquilimab or a placebo without knowing which one they get, to see how well the drug works.

What are the potential side effects?

Since this summary doesn't specify side effects, it can be assumed that potential side effects may include typical reactions seen in allergy and immunotherapy trials such as injection site reactions, headaches, fatigue, or respiratory symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have a positive reaction to asthma tests.

Select...

I am between 18 and 65 years old with stable allergic asthma.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a lung condition that is not allergic asthma.

Select...

I am not trying to get pregnant and am using effective birth control.

Select...

My asthma or lung infection has gotten worse in the last 6 weeks.

Select...

I have been treated with a c-Kit inhibitor before.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ from signing the informed consent form (icf) through end of trial (eot) visit (up to 4.5 months)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~from signing the informed consent form (icf) through end of trial (eot) visit (up to 4.5 months)

This trial's timeline: 3 weeks for screening, Varies for treatment, and from signing the informed consent form (icf) through end of trial (eot) visit (up to 4.5 months) for reporting.